Jazz Pharma Reports Material Agreement & New Financial Obligation

TL;DR

**JAZZ just reported a new material agreement and financial obligation, details pending.**

AI Summary

Jazz Pharmaceuticals plc filed an 8-K on January 25, 2024, reporting an event on January 19, 2024, related to entering a material definitive agreement and creating a direct financial obligation. While the filing indicates these events, it does not provide specific details about the nature of the agreement or the financial obligation. This matters to investors because material agreements and new financial obligations can significantly impact a company's financial health, future prospects, and stock valuation, and the lack of detail here means investors need to await further information to assess the impact.

Why It Matters

This filing signals that Jazz Pharmaceuticals has undertaken a new significant financial commitment or agreement, which could affect its balance sheet and future earnings. Investors should monitor for subsequent disclosures to understand the specific terms and potential impact.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement and a direct financial obligation, which inherently carry financial risk, but the lack of specific details prevents a full assessment of the magnitude of this risk.

Analyst Insight

A smart investor would note the reported material agreement and financial obligation but await further detailed disclosures from Jazz Pharmaceuticals plc before making any investment decisions, as the current filing lacks specific financial terms or implications.

Key Players & Entities

• Jazz Pharmaceuticals plc (company) — the registrant filing the 8-K
• January 19, 2024 (date) — date of the earliest event reported
• January 25, 2024 (date) — date the 8-K was filed
• 001-33500 (other) — Commission File No. for Jazz Pharmaceuticals plc
• 98-1032470 (other) — IRS Employer Identification No. for Jazz Pharmaceuticals plc

FAQ

Key Financial Figures

• $0.0001 — istered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Mar
• $201,909,488.38 — llar Term Loans") and Jazz Lux borrowed $201,909,488.38 aggregate principal amount of additiona
• $2,722,500,000 — g the Repricing Amendment, each totaled $2,722,500,000. The Tranche B-1 Dollar Term Loans be

Filing Documents

• d707707d8k.htm (8-K) — 28KB
• d707707dex101.htm (EX-10.1) — 1423KB
• 0001193125-24-015517.txt ( ) — 1900KB
• jazz-20240119.xsd (EX-101.SCH) — 3KB
• jazz-20240119_lab.xml (EX-101.LAB) — 18KB
• jazz-20240119_pre.xml (EX-101.PRE) — 11KB
• d707707d8k_htm.xml (XML) — 3KB

01

Item 1.01. Entry into a Material Definitive Agreement. For the purpose of repricing the outstanding U.S. dollar term loans incurred on May 5, 2021 (the "Initial Dollar Term Loans"), on January 19, 2024, Jazz Financing Lux S. r.l., a private limited liability company ( socit responsabilit limite ) incorporated and existing under the laws of Luxembourg ("Jazz Lux") and wholly owned subsidiary of Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in Ireland (the "Company"), entered into an amendment (the "Repricing Amendment") to the Credit Agreement, dated May 5, 2021, by and among Jazz Lux and certain other subsidiaries of the Company, as borrowers (collectively with the Company and Jazz Lux, the "Borrowers"), the lenders and issuing banks from time to time party thereto, Bank of America, N.A., as administrative agent and U.S. Bank Trust Company, National Association, as collateral trustee (as amended by the Repricing Amendment, the "Amended Credit Agreement"). Upon entry into the Amended Credit Agreement, certain existing lenders converted outstanding Initial Dollar Term Loans into a new tranche of U.S. dollar term loans (the "Tranche B-1 Dollar Term Loans") and Jazz Lux borrowed $201,909,488.38 aggregate principal amount of additional Tranche B-1 Dollar Term Loans, the proceeds of which were used to repay the outstanding Initial Dollar Term Loans that were not converted. The Tranche B-1 Dollar Term Loans are a separate class of term loans under the Amended Credit Agreement with the same material terms (including with respect to maturity, prepayment, security, covenants and events of default) as the previously outstanding Initial Dollar Term Loans as described under Item 2.03 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 5, 2021 , which description is incorporated herein by reference, with the interest rate amended as described below. The principal amount of Initial Dollar Term

03

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amendment No. 1, dated as of January 19, 2024, by and among Jazz Pharmaceuticals Public Limited Company, the other borrowers from time to time party thereto, the lenders and issuing banks from time to time party thereto, Bank of America, N.A., as administrative agent, and U.S. Bank Trust Company, National Association, as collateral trustee. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Patricia Carr Name: Patricia Carr Title: Principal Accounting Officer and Interim Principal Financial Officer Date: January 25, 2024

View Full Filing

View this 8-K filing on SEC EDGAR